Innate immune signatures to a partially-efficacious HIV vaccine predict correlates of HIV-1 infection risk.
The pox-protein regimen tested in the RV144 trial is the only vaccine strategy demonstrated to prevent HIV-1 infection. Subsequent analyses identified antibody and cellular immune responses as correlates of risk (CoRs) for HIV infection. Early predictors of these CoRs could provide insight into vacc...
Main Authors: | Erica Andersen-Nissen, Andrew Fiore-Gartland, Lamar Ballweber Fleming, Lindsay N Carpp, Anneta F Naidoo, Michael S Harper, Valentin Voillet, Nicole Grunenberg, Fatima Laher, Craig Innes, Linda-Gail Bekker, James G Kublin, Ying Huang, Guido Ferrari, Georgia D Tomaras, Glenda Gray, Peter B Gilbert, M Juliana McElrath |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2021-03-01
|
Series: | PLoS Pathogens |
Online Access: | https://doi.org/10.1371/journal.ppat.1009363 |
Similar Items
-
Benign ethnic neutropenia in a South African population, and its association with HIV acquisition and adverse event reporting in an HIV vaccine clinical trial.
by: Rephaim Mpofu, et al.
Published: (2021-01-01) -
Human gut microbiota is associated with HIV-reactive immunoglobulin at baseline and following HIV vaccination.
by: Jacob A Cram, et al.
Published: (2019-01-01) -
The epidemiology of dual HIV infection in the KwaZulu-Natal Anti-Retroviral Roll-out Programme.
by: Naidoo, Anneta Frances.
Published: (2011) -
HIV counselling
by: Linda-Gail Bekker
Published: (2002-07-01) -
Hope for HIV control in southern Africa: The continued quest for a vaccine.
by: Linda-Gail Bekker, et al.
Published: (2017-02-01)